FDA WILL ISSUE BATCH SIZE POLICY CLARIFICATION

FDA WILL ISSUE BATCH SIZE POLICY CLARIFICATION following meetings with the Generic Pharmaceutical Manufacturers Association and the National Association of Pharmaceutical Manufacturers. A clarification of the interim policy could come as early as the week of Sept. 3, FDA said. FDA Office of Generic Drugs officials met with GPIA Aug. 22 and NAPM Aug. 28 to discuss a guidance issued in July specifying batch sizes for ANDA bio-equivalence testing ("The Pink Sheet" July 23, p. 9). Mylan also has met with the agency on the issue. The associations have taken issue with several points of the policy statement but particularly object to the requirement that biotesting batches be produced on the same equipment as used for scaled-up production. Noting that for oral dosage ANDAs the guidance requires that 100,000 units or 10% of the proposed production batch be used in a biotest, the groups maintain that a batch of this size cannot be made on equipment intended to manufacture one mil. tablets. GPIA maintains that production of generic products is at a standstill pending resolution of this issue. In the July guidance, FDA noted that there is "limited supporting technical data on which to base a policy allowing for less-than-full, commercial-scale test batches." However, the agency reports that "the policy as currently stated does have broad support in the Division of Generic Drugs and is based primarily on a judgment that it appears to be -- for industry and for the consumer -- both practical and reasonable." GPIA and NAPM have suggested that FDA permit smaller scale-up equipment as long as it is validated. In addition, they have asked for a clarification of the definition of the 100,000-unit test batch size, specifically whether it allows for the normal 5% to 10% loss of material or whether instead companies should produce a batch size of 120,000 units to make up for losses normally occuring during production. NAPM also has recommended that FDA allow R&D personnel to be involved in the manufacturing process. GPIA maintains that FDA should not implement any changes in the original batch size policy established in January 1988 until the agency holds a workshop to collect technical data. In an Aug. 23 letter to Office of Generic Drugs Acting Director Bruce Burlington, GPIA said that it hopes that "with respect to allowable changes in equipment size, there will be no interim reversal of the policy, which was announced by the Division of Bioequivalence in January 1988, until technical data to be presented at this workshop is fully evaluated." FDA is said to be planning such a workshop for February 1990. Although the batch policy guidance addresses only oral dosage non-antibiotic ANDAs, GPIA suggested in its letter that "all immediate release dosage forms, including antibiotics, be addressed at FDA's upcoming workshop on preapproval and postapproval batch sizes and scale-ups."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By 

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.